Table 1B.
Studies utilizing antibodies IL33/ST2 in tumor models in mice.
| Reference | Antibody | Cancer model | Result | MCs analyzed |
|---|---|---|---|---|
| Guabiraba et al. (123) | Anti-IL33, anti-mouse, clone 396118, MAB3626, R&D | CT26 colon cancer cell line subcutaneous | aIL33+Irinotecan -> anti-tumor effect | No |
| Nakagawa et al. (105) | Anti-IL33, R&D | KTC-K19CreERT extrahepatic cholangiocarcinoma mice | Anti-tumor effect | No |
| Wu et al. (124) | Anti-IL33, anti-human, MAB36254, R&D | Renal cancer cell lines 786O and OSRC2 subcutaneous in nude BalbC | Anti-tumor effect | No |
| Anti-ST2, anti-human, Clone MAB523, R&D | Anti-tumor effect | No | ||
| Zhou et al. (125) | Rabbit anti-mouse, R&D | CT26 colon cancer cell line subcutaneous | Anti-tumor effect | No |
| Rabbit anti-mouse, R&D | Anti-tumor effect | No | ||
| Kim et al. (126) | Anti-ST2, anti-mouse, clone 245707, MAB10041, R&D | KrasG12DxCCSP-Cre lung cancer model | Anti-tumor effect | No |
| Lin et al. (127) | Anti-ST2, monoclonal anti-human, R&D | Ln229 glioma cell line subcutaneous in NSG mice | Anti-tumor effect | NSG are MC-def. |
| Maywald et al. (70) | Anti-ST2, mu-IgG1-FC–anti-muST2, Amgen | ApcMin intestinal cancer model | Anti-tumor effect | Yes, MC number + activation decreased in IL33KO/anti-St2 treated tumors |
| Kudo-Saito et al. (128) | Anti-IL33, anti-mouse, R&D | B16F10 melanoma subcutaneous and intravenous | Anti-tumor | Yes, MC increased in BM metastasis |